Insight

Laura Bukavina: A study of 221 patients found no survival benefit from NAC in bladder cancer

Laura Bukavina/X

Jan 26, 2025, 15:32

Laura Bukavina: A study of 221 patients found no survival benefit from NAC in bladder cancer

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X about a recent paper by Cagri Akpinar et al. published in International Journal of Urology:

“Variant histology in bladder cancer poses a unique treatment challenge. A study of 221 patients found no survival benefit from NAC.

No significant differences in outcomes (OS: HR 1.88, p=0.14; CSS: HR 1.34, p=0.50; RFS: HR 1.13). Use NAC cautiously in VH, as response may hinge on the % of urothelial component.”

“The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association”

Authors: Cagri Akpinar, Evren Suer, Bülent Akdogan, Volkan Izol, Serdar Celik, Guven Aslan, Hacı Murat Akgul, Deniz Bolat, Sinan Sozen, Mutlu Deger, Sumer Baltaci.

Laura Bukavina: A study of 221 patients found no survival benefit from NAC in bladder cancer

More posts featuring Laura Bukavina.

bladder cancer Bülent Akdogan Cagri Akpinar cancer Deniz Bolat Evren Suer Guven Aslan Hacı Murat Akgul Laura Bukavina Mutlu Deger OncoDaily Oncology Serdar Celik Sinan Sozen Sumer Baltaci Volkan Izol

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization